Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Dermatologic 1

Conditions

Melanoma 5Prostatic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 58Nivolumab 37aldesleukin 16Cyclophosphamide 15atezolizumab 12Specimen Handling 11Radiosurgery 10Paclitaxel 10Magnetic Resonance Spectroscopy 10Ipilimumab 9Interleukin-2 9fludarabine 8fludarabine phosphate 7Docetaxel 7Carboplatin 7avelumab 6Radiotherapy 6durvalumab 5Peripheral Blood Stem Cell Transplantation 5Immune Checkpoint Inhibitors 5Cisplatin 5Bevacizumab 5tislelizumab 4temsirolimus 4spartalizumab 4Sirolimus 4Pemetrexed 4Oxaliplatin 4Leucovorin 4Cryosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Hydroxychloroquine × Dermatologic × Clear all
NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡